Total Payments
$4,553
2024 Payments
$818.02
Companies
43
Transactions
306
Medicare Patients
9,331
Medicare Billing
$716,452
Payment Breakdown by Category
Food & Beverage$4,514 (99.2%)
Education$38.44 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,514 | 304 | 99.2% |
| Education | $38.44 | 2 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $685.05 | 52 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $425.66 | 32 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $329.19 | 21 | $0 (2024) |
| Novo Nordisk Inc | $298.48 | 22 | $0 (2024) |
| PFIZER INC. | $267.65 | 17 | $0 (2024) |
| Lilly USA, LLC | $243.07 | 17 | $0 (2023) |
| Amgen Inc. | $234.24 | 13 | $0 (2024) |
| GlaxoSmithKline, LLC. | $212.44 | 15 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $168.18 | 10 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $142.18 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $818.02 | 53 | ABBVIE INC. ($205.91) |
| 2023 | $913.12 | 62 | AbbVie Inc. ($268.05) |
| 2022 | $647.98 | 42 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($158.71) |
| 2021 | $860.26 | 59 | AbbVie Inc. ($131.29) |
| 2020 | $527.90 | 36 | Lilly USA, LLC ($153.54) |
| 2019 | $193.31 | 14 | GlaxoSmithKline, LLC. ($38.31) |
| 2018 | $279.66 | 24 | Allergan Inc. ($57.22) |
| 2017 | $312.28 | 16 | Arbor Pharmaceuticals, Inc. ($70.16) |
All Payment Transactions
306 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $18.99 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Inflammation | ||||||
| 11/21/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.03 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TRINTELLIX (Drug) | Food and Beverage | In-kind items and services | $19.25 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $15.51 | General |
| Category: RESPIRATORY | ||||||
| 11/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.73 | General |
| Category: NEUROSCIENCE | ||||||
| 11/11/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $18.93 | General |
| Category: Genetic Disease | ||||||
| 11/04/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $15.95 | General |
| Category: RESPIRATORY | ||||||
| 10/30/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $14.36 | General |
| Category: Respiratory | ||||||
| 10/17/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $3.73 | General |
| Category: NEUROSCIENCE | ||||||
| 10/15/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.42 | General |
| Category: NEUROSCIENCE | ||||||
| 10/03/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: Genetic Disease | ||||||
| 09/16/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $13.78 | General |
| 09/11/2024 | Indivior Inc. | SUBLOCADE (Drug) | Food and Beverage | In-kind items and services | $20.91 | General |
| Category: OUD | ||||||
| 09/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.39 | General |
| Category: NEUROSCIENCE | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Respiratory | ||||||
| 09/04/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $4.80 | General |
| Category: NEUROSCIENCE | ||||||
| 08/29/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $18.03 | General |
| Category: Genetic Disease | ||||||
| 08/14/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $4.19 | General |
| Category: NEUROSCIENCE | ||||||
| 07/31/2024 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $18.31 | General |
| Category: Genetic Disease | ||||||
| 07/31/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $13.11 | General |
| Category: Gastroenterology | ||||||
| 07/30/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Psychology/Psychiatric | ||||||
| 07/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $6.31 | General |
| Category: NEUROSCIENCE | ||||||
| 07/22/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: NEUROSCIENCE | ||||||
| 07/11/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Biological | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 567 | 1,039 | $128,939 | $63,047 |
| 2022 | 21 | 649 | 1,277 | $129,884 | $59,140 |
| 2021 | 49 | 3,965 | 11,401 | $594,712 | $298,554 |
| 2020 | 54 | 4,150 | 15,501 | $574,189 | $295,711 |
Total Patients
9,331
Total Services
29,218
Medicare Billing
$716,452
Procedure Codes
136
All Medicare Procedures & Services
136 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 92 | 315 | $37,438 | $18,520 | 49.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 90 | 149 | $24,799 | $14,555 | 58.7% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 92 | 184 | $20,240 | $11,130 | 55.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 34 | 47 | $10,105 | $6,086 | 60.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 21 | 32 | $5,280 | $2,871 | 54.4% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 45 | 75 | $5,250 | $2,810 | 53.5% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 16 | 35 | $4,900 | $2,784 | 56.8% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 22 | 45 | $4,950 | $2,193 | 44.3% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2023 | 64 | 65 | $7,058 | $926.99 | 13.1% |
| 93018 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with review by physician | Facility | 2023 | 64 | 65 | $4,702 | $621.27 | 13.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 12 | 12 | $1,126 | $343.20 | 30.5% |
| 93227 | Electrocardiogram (ecg) 2-day continuous with review by health care professional | Facility | 2023 | 15 | 15 | $3,091 | $207.60 | 6.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 86 | 311 | $33,365 | $16,675 | 50.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 75 | 120 | $22,491 | $11,785 | 52.4% |
| 99218 | Initial hospital observation care per day, typically 30 minutes | Facility | 2022 | 54 | 114 | $15,822 | $8,205 | 51.9% |
| 99217 | Hospital observation care on day of discharge | Facility | 2022 | 69 | 104 | $10,661 | $5,390 | 50.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 63 | 98 | $9,554 | $5,272 | 55.2% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Office | 2022 | 26 | 106 | $10,207 | $5,265 | 51.6% |
| 99225 | Follow-up observation care per day, typically 25 minutes | Facility | 2022 | 16 | 22 | $2,310 | $1,182 | 51.1% |
| 99318 | Nursing facility annual assessment, typically 30 minutes | Office | 2022 | 13 | 13 | $1,810 | $924.59 | 51.1% |
| 87635 | Amplifed dna or rna probe detection of severe acute respiratory syndrome coronavirus 2 (covid-19) antigen | Office | 2022 | 15 | 15 | $1,500 | $769.65 | 51.3% |
| 99283 | Emergency department visit for problem of moderate severity | Facility | 2022 | 12 | 12 | $2,248 | $668.42 | 29.7% |
| 93016 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision by physician | Facility | 2022 | 40 | 43 | $4,546 | $660.77 | 14.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 28 | 31 | $3,532 | $657.64 | 18.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 13 | $1,995 | $636.85 | 31.9% |
About Dr. Anthony Carter, MD
Dr. Anthony Carter, MD is a Internal Medicine healthcare provider based in Tompkinsville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/15/2006. The National Provider Identifier (NPI) number assigned to this provider is 1104890276.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Anthony Carter, MD has received a total of $4,553 in payments from pharmaceutical and medical device companies, with $818.02 received in 2024. These payments were reported across 306 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($4,514).
As a Medicare-enrolled provider, Carter has provided services to 9,331 Medicare beneficiaries, totaling 29,218 services with total Medicare billing of $716,452. Data is available for 4 years (2020–2023), covering 136 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Internal Medicine
- Location Tompkinsville, KY
- Active Since 02/15/2006
- Last Updated 07/26/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1104890276
Products in Payments
- VRAYLAR (Drug) $549.13
- XIFAXAN (Drug) $395.08
- Otezla (Drug) $154.21
- SOLIQUA 100/33 (Biological) $150.41
- FARXIGA (Drug) $128.51
- UBRELVY (Drug) $127.46
- NUEDEXTA (Drug) $118.52
- ENTRESTO (Drug) $114.84
- XARELTO (Drug) $104.84
- AREXVY (Drug) $101.15
- Omnipod (Device) $100.27
- ELIQUIS (Drug) $90.60
- BREZTRI (Drug) $90.37
- TRINTELLIX (Drug) $88.10
- EMGALITY (Drug) $87.52
- GIVLAARI (Drug) $73.44
- TRULICITY (Drug) $72.87
- Tresiba (Drug) $68.38
- ACCRUFER (Drug) $60.41
- Horizant (Drug) $59.74
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.